Adam Slutsky > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices
100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Adam Slutsky
Position
Partner
Career
Adam Slutsky is a partner in Goodwin’s Securities & Shareholder Litigation group and a member of the firm’s Post Closing Disputes and Life Sciences Disputes groups. He focuses his practice on securities and complex commercial litigation, including fiduciary duty claims, disputes arising from corporate mergers and acquisitions, securities class action defense, and regulatory investigations, and he regularly advises clients and their boards of directors on disclosure-related issues and litigation risk mitigation. Mr. Slutsky, whose practice is national in scope, has extensive experience representing clients in Delaware state and federal courts on groundbreaking issues of Delaware law. Clients include public and private companies in technology and life sciences, their boards and officers, and private equity firms and their partners. Mr. Slutsky is recognized by The Legal 500 U.S. for his M&A litigation practice.
Education
JD, Fordham University School of Law (magna cum laude, Order of the Coif) / BS, Cornell University
Lawyer Rankings
United States > Dispute resolution > M&A litigation: defense
Goodwin has a unique strategic focus on key industry sectors, notably life sciences, technology, and real estate, handling transactions and consequent litigation across the US, Europe and Asia. The firm also has a large private equity practice that is among the leading players in the expansive middle market sector, and this also generates work for the litigation department. Deborah Birnbach leads the practice, as well as being a key member of the life sciences group, and her track record in securities and shareholder litigation is notable. Adam Slutsky is also active in disputes in after healthcare deals. All lawyers are based in Boston. Michael Jones left to join Holland & Knight LLP.
United States > Dispute resolution > Securities litigation: defense
Goodwin is known as one of the leading life sciences firms in the US, as well as a prominent player in matters concerning technology companies and REITs. The firm is handling a growing volume of class actions, derivative cases and SEC investigations, particularly for tech companies. Clients note that the firm’s ‘judgement, subject knowledge and guidance is outstanding’ and are ‘impressed with their technical insights combined with practical experience’. Deborah Birnbach leads the practice from Boston, where Adam Slutsky and Caroline Bullerjahn are among the standout partners. Birnback and Bullerjahn obtained full dismissal of a securities class action against biopharma company Alkermes plc, which was accused of making misstatements and omissions regarding the development program for a clinical stage drug for a major depressive disorder. Daniel Roeser in New York is representing underwriting syndicates in a putative securities class action filed in Florida federal court against Axogen. Key partner Brian Pastuszenski retired, but Jonathan Shapiro in San Francisco from Baker Botts L.L.P. (who is ‘a highly capable attorney with a dynamic and empathetic personality’) reinforces the firm’s stronghold in its key sectors. Jonathan Hecht in Washington DC joined from the SEC and is ‘a transformative presence’ in enforcement matters.
Lawyer Rankings
- M&A litigation: defense United States > Dispute resolution
- Securities litigation: defense United States > Dispute resolution
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Industry focus > Education
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Securities litigation: defense
- Finance > Capital markets: debt offerings
- International Trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Real estate > Real estate
- M&A/corporate and commercial > Shareholder activism
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Healthcare > Service providers
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)